Login
Companies $FHTX
$1.76 -$0.03 (1.68%) After hours
Foghorn Therapeutics Inc. logo

Foghorn Therapeutics Inc.

foghorntx.com

What Do They Do?

Develops small-molecule drug candidates targeting the gene-control system for patients with cancer and immune and inflammatory diseases.

How Do They Make Money?

Foghorn earns collaboration revenue from partners for licenses and drug-discovery and development work. Agreements can include upfront payments, development milestones and royalties tied to partner sales.

FY2025 revenue

Who Are Their Customers?

Lilly is the customer for Foghorn’s collaboration work, including joint oncology development and platform-based discovery programs.

Do Revenues Turn Into Profits?

No. It lost $74.3M in FY2025.

Operating income, FY2025
−279% of revenue
▲ +16% (Loss) vs FY2024 (−$102.7M, −454%)
Net income, FY2025
−240% of revenue
▲ +14% (Loss) vs FY2024 (−$86.6M, −383%)
Free cash flow, FY2025
−279% of revenue
▲ +15% (Loss) vs FY2024 (−$101.3M, −448%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +925%
vs $8.2M in Q3 FY2025
Net income
▲ Turned profitable
vs −$15.8M in Q3 FY2025
  • Sep 25, 2026 Foghorn and Lilly stopped advancing FHD-909 and reprioritized the portfolio The companies also stopped the SMARCA2 degrader program; Foghorn shifted resources to proprietary programs and planned a workforce reduction.

Growing. Revenue grew 23.4x in 4 years, from $1.3M in FY2021 to $30.9M in FY2025, about 120% a year.

Clinical pipeline focus The older report described clinical-stage cancer drug candidates; the latest report centered development on a Lilly-partnered candidate and described the other candidates as preclinical.

Who Do They Compete With?

Competes with Arvinas, C4 Therapeutics, Kymera Therapeutics, Nurix Therapeutics, Amphista, CellCentric, IDEAYA Biosciences, Novartis, Plexium, Opna Bio, Relay Therapeutics, SK Bio, and Tolremo Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support